TITLE:
Study Evaluating rFIX; BeneFIX in Hemophilia B

CONDITION:
Hemophilia B

INTERVENTION:
rFIX

SUMMARY:

      The primary objective of this clinical research study is to assess the safety and efficacy
      of rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B
      (FIX:C 2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and
      minor surgical procedures).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 12 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Hemophilia B (FIX:C less than 2%)

          -  Previous treatment of at least 150 exposure days using any FIX product

          -  12 years of age and older

        Exclusion Criteria:

          -  The patient has a currently detectable factor IX inhibitor or a history of
             inhibitors. (A family history of inhibitors will not exclude the patient)

          -  Known hypersensitivity to protein pharmaceuticals or agents related to the test
             article, e.g. hamster proteins

          -  Patient has a genetic coagulation disorder other than hemophilia B
      
